Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

off-label sales of Actimmune for the treatment of IPF, which InterMune does not promote. Revenue from the collaboration with Roche was $1.6 million in the first six months of 2008, compared with $11.6 million in the same period of 2007.

R&D expenses were $52.6 million in the first six months of 2008, an 8% decrease compared to $57.4 million in the same period of 2007. This decrease was primarily due to termination of the INSPIRE Phase 3 trial of Actimmune in March 2007. G&A expenses of $14.6 million in the first half of 2008 were approximately 12% lower than $16.6 million in the first six months of 2007, reflecting headcount reduction and cost-control initiatives following termination of the INSPIRE trial.

Second Quarter Highlights

Pirfenidone:

-- Shionogi & Co., Ltd of Japan, which has rights to pirfenidone in

Japan, reported results of its Phase 3 study in Japan at the

American Thoracic Society meeting in Toronto on May 20. Following

the presentation, InterMune noted the following:

-- The baseline characteristics of patients enrolled in the

Shionogi Phase 3 trial and the InterMune Phase 3 CAPACITY

program are extremely similar.

-- The Shionogi Phase 3 trial confirmed the results reported by

Shionogi from their Phase 2 trial; notably a positive effect of

pirfenidone on the rate of decline in Vital Capacity over time

and an acceptable safety profile.

-- The number of patient dropouts in the Shionogi study was

consistent with that of other multi-center studies of other

compounds in IPF and the nature of the dropouts in the Shionogi

study may have underestimated the treatment effect of

pirfenidone.

-- The study conduct of CAPACITY is excellent and InterMune

expects to achiev
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2
... FRANCISCO, Oct. 2 Epiphany Biosciences,Inc. announced today ... of,Lead Director. Dr. Sanders is a highly experienced ... of Genentech.,He has also served as chief executive ... the board from 1992-1995. In addition, Dr. Sanders ...
... VIEJO, Calif., Oct. 2 Clarient, Inc.,(Nasdaq: ... testing services,resource for pathologists, oncologists and the pharmaceutical ... is featured in an,exclusive interview on WallSt.net,s 3-Minute ... overview of the company, and the,significance of the ...
... LA JOLLA, Calif., Oct. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: ... successful End-of-Phase II,meeting for tezampanel with the U.S. Food ... a review of the Phase II data, the FDA ... tezampanel in acute,migraine. The FDA also confirmed that the ...
Cached Biology Technology:[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 2TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 3TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 4
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... KINGSTON, R.I. March 1, 2010 In one of ... of natural and social scientists from the University of Rhode ... among the most important factors driving the success of marine ... marine reserve is just about coral, fish and other aquatic ...
... researchers have found a way to stitch graphene and ... offers new paths of exploration for materials scientists. ... in microelectronics that scale well below the limitations of ... the lab of Pulickel Ajayan, Rice,s Benjamin M. and ...
... Moines, Iowa March 1, 2010 You may have ... bonobos living at Great Ape Trust, than you thought. And ... scientists more about the effect of culture on neurological disorders ... universal language, an alternative to spoken words to convey a ...
Cached Biology News:Scientists find community involvement, not only enforcement, drives success of marine reserves 2Rice researchers make graphene hybrid 2Rice researchers make graphene hybrid 3If bonobo Kanzi can point as humans do, what other similarities can rearing reveal? 2If bonobo Kanzi can point as humans do, what other similarities can rearing reveal? 3
... C-1-tetrahydrofolate synthase, cytoplasmic ... Methylenetetrahydrofolate dehydrogenase (EC ... (EC 3.5.4.9); Formyltetrahydrofolate ... [Source:Uniprot/SWISSPROT;Acc:P11586] ...
Request Info...
Lipid-rich bovine serum albumin for cell culture (1). It is chromatographically purified and has an IgG content 0.1% (w/w)....
Chicken anti-EEA1...
Biology Products: